Search results
Results From The WOW.Com Content Network
Stryker Corporation (NYSE: SYK ) has approached Boston Scientific Corporation (NYSE: BSX ) with a buyout opportunity, according to The Wall Street Journal . Boston Scientific shares spiked 11 ...
Boston Scientific: Guidant: 24.6 38 With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). 26 2006
Net income. £6.2 million (2007) [1] Number of employees. 89 (2007) [1] Website. www.biocompatibles.com. Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, [2] which was, in turn, acquired by Boston Scientific in 2019. [3] [4]
By Sriparna Roy. (Reuters) -Boston Scientific will buy Silk Road Medical in a $1.16 billion deal, the company said on Tuesday, adding medical devices used for stroke prevention. Boston, which ...
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. [2] Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as ...
For premium support please call: 800-290-4726 more ways to reach us
Boston Scientific was formed June 29, 1979, in Watertown, Massachusetts, as a holding company for the medical products company, Medi-Tech, Inc., and to position the company for growth in interventional medicine. [ 6] Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the ...
Boston Scientific's revenue peaked in 2007 at $8.4 billion. Last year, the comparable number was $7.2 billion. In 2012, Boston Scientific lost more than $4 billion, much of it due to special charges.